- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
Progesterone could help treat breast cancer
9 July 2015 • Author: Victoria White
Around half of all breast cancer patients could one day benefit from having the cheap and widely-available female hormone progesterone added to their treatment.
That’s according to new Cancer Research UK-funded research.
Tumours fuelled by the female hormone oestrogen are treated with drugs like tamoxifen to block oestrogen receptors, which cause cancer cells to grow.
Women whose tumours have progesterone receptors as well are known to have a better outlook. But for decades scientists have been unable to pinpoint why.
Scientists at Cancer Research UK’s Cambridge Research Institute and the University of Adelaide have revealed how the progesterone receptor ‘talks to’ the oestrogen receptor in breast cancer cells to change their behaviour, ultimately slowing down tumour growth.
Adding progesterone to drugs that target the oestrogen receptor potentially beneficial
Cancer Research UK’s Dr Jason Carroll, who led the study with Professor Wayne Tilley at the University of Adelaide in Australia, said, “We’ve used cutting-edge technology to tease out the crucial role that progesterone receptors play in breast cancer – a mystery that has baffled scientists for many years.
“This important laboratory research helps explain why some breast cancer patients have a better outlook. Crucially, it provides a strong case for a clinical trial to investigate the potential benefit of adding progesterone to drugs that target the oestrogen receptor, which could improve treatment for the majority of hormone-driven breast cancers.”
There are around 50,000 new cases of breast cancer each year in the UK and around half could potentially benefit from this finding, according to the researchers.
Dr Emma Smith, senior science communication officer at Cancer Research UK, said, “This exciting study in cells shows how a cheap, safe, and widely available drug could potentially improve treatment for around half of all breast cancer patients. Thanks to research, almost 70%of women now survive breast cancer beyond 20 years – but so much more must be done and we won’t stop until we find cures for all forms of the disease.”
The research is published in Nature.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe Kaiser Optical Systems Inc. L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Lonza MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. Peak Scientific PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics